Drug patent expirations and the speed of generic entry

Health Services Research

Volumn 32, Issue 1, 1997, Pages 87-101

  Bae, Jay P ^a  

^a NONE

Author keywords

generic drug entry and patent; Pharmaceuticals

Indexed keywords

GENERIC DRUG;

ARTICLE; DRUG MARKETING; DRUG RESEARCH; DRUG USE; PATENT; STATISTICAL ANALYSIS;

DRUG INDUSTRY; DRUGS, GENERIC; INCOME; MODELS, ECONOMIC; PATENTS; REGRESSION ANALYSIS; RESEARCH; TIME FACTORS; UNITED STATES;

EID: 0030903260     PISSN: 00179124     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Ciba-Geigy Corporation. 1994. Trends and Forecasts, 1994 Edition. Ciba Pharmacy Benefit Report. Ciba-Geigy Corporation, Summit, NJ.
2. 1995. Trends and Forecasts, 1995 Edition. Ciba Pharmacy Benefit Report. CibaGeigy Corporation, Summit, NJ.
3. Caves, R., M. Winston, and M. Hurwitz. 1991. "Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry: An Exploratory Analysis." Brookings Papers on Economic Activity: Microeconomics. Washington, DC: Brookings Institution.
4. Comanor, W. 1986. "The Political Economy of the Pharmaceutical Industry. "Journal of Economic Literature 24 (September): 1178-1217.
5. Comanor, W., and S. Schweitzer. 1994. "Pharmaceuticals." In The Structure of American Industry, 9th ed. Edited by W. Adams andj. Brock. Englewood Cliffs, NJ: Prentice Hall.
6. Grabowski, H. G., andj. M. Vernon. 1992. "Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act." Journal of Law and Economics 21 (October): 331-50.
7. 1986. "Longer Patents for Lower Imitation Barriers: The 1984 Drug Act." American Economics Review, AEA Papers and Proceedings 76 (May): 195-98.
8. Griliches, Z., and I. Cockburn. 1994. "Generics and New Goods in Pharmaceutical Price Indexes." American Economic Review 84 (December): 1213-32.
9. Hurwitz, M., and R. Caves. 1988. "Persuasion or Information? Promotion and the shares of Brand Name and Generic Pharmaceuticals." Journal of Law and Eco-nomics 31 (October): 299-320.
10. Masson, A., and R. Steiner. 1985. "Generic Substitution and Prescription Drug Prices: Economic Effects of State Drug Product Selection Laws." Washington, DC: Federal Trade Commission, Bureau of Economics.
11. Medical Economics Data Production Company. 1994. Physicians'Desk Reference, 48th ed. Montevale, NJ: Medical Economics Data Production Company.
12. Pharmaceutical Manufacturers Association. 1993. PAIA Annual Survey Report: Trends in U.S. Pharmaceutical Sales andR&D. Washington, DC: PMA.
13. Schwartzman, D. 1976. Innovations in the Pharmaceutical Industry. Baltimore, MD:Johns Hopkins University Press.
14. Statman, M. 1981. "The Effects of Patent Expiration on the Market Position of Drugs." In Drugs and Health: Economic Issues and Policy Objectives. Edited by R. Helms. Washington, DC: American Enterprise Institute.
15. U.S. Food and Drug Administration. Various. Office of Generic Drugs Quantitative Report: ANDAs andAADAs. Washington, DC: FDA.
16. Various. FDA Drug and Device Product Approvals. Washington, DC: Division of Drug Information Resources, OM, CDER, FDA.